RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer-Reference-Cited by-同舟云学术

RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer

Published:2022-07-13 Issue:13 Volume:96 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Olczak Pola¹,Matsui Ken²,Wong Margaret¹,Alvarez Jade¹,Lambert Paul³,Christensen Neil D.⁴⁵,Hu Jiafen⁴⁵^ORCID,Huber Bettina⁶,Kirnbauer Reinhard⁶,Wang Joshua W.²,Roden Richard B. S.¹^ORCID

Affiliation:

1. Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA

2. Pathovax LLC, Baltimore, Maryland, USA

3. McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, USA

4. The Jake Gittlen Laboratories for Cancer Research, Pennsylvania State University, College of Medicine, Hershey, Pennsylvania, USA

5. Department of Pathology, Pennsylvania State University, College of Medicine, Hershey, Pennsylvania, USA

6. Department of Dermatology, Medical University of Vienna, Vienna, Austria

Abstract

Licensed preventive HPV vaccines are composed of VLPs derived by expression of major capsid protein L1. They confer protection generally restricted to infection by the αHPVs targeted by the up-to-9-valent vaccine, and their associated anogenital cancers and genital warts, but do not target βHPV that are associated with CSCC in EV and immunocompromised patients.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.00566-22

Reference87 articles.

1. Classification of papillomaviruses

2. Risk Factors for Dysplasia in Recurrent Respiratory Papillomatosis in an Adult and Pediatric Population

3. Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer

4. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deficiency in Ever2 does not increase susceptibility of mice to pathogenesis by the mouse papillomavirus, MmuPV1;Journal of Virology;2024-07-23

2. Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review;Vaccines;2024-02-23

3. Improving the efficacy of peptide vaccines in cancer immunotherapy;International Immunopharmacology;2023-10

4. Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model;Vaccine;2023-07

5. Factors Associated with HPV Knowledge Among Professionals in the City of Francisco Beltrão, Brazil;Journal of Community Health;2023-03-15